Valuation: OraSure Technologies, Inc.

Market Cap 246M 214M 202M 184M 344M 23.56B 345M 2.42B 934M 11.98B 922M 902M 38.54B P/E 2026 *
-5.39x
P/E 2027 * -4.4x
Enterprise Value 246M 214M 202M 184M 344M 23.56B 345M 2.42B 934M 11.98B 922M 902M 38.54B EV / Sales 2026 *
2.01x
EV / Sales 2027 * 1.84x
Free-Float
93.64%
Yield 2026 *
-
Yield 2027 * -
1 day+2.01%
1 week+9.54%
Current month-0.84%
1 month-5.07%
3 months-16.24%
6 months+22.76%
Current year+47.11%
1 week 3.22
Extreme 3.22
3.58
1 month 3.14
Extreme 3.145
3.93
Current year 2.33
Extreme 2.33
4.58
1 year 2.08
Extreme 2.08
4.58
3 years 2.08
Extreme 2.08
8.45
5 years 2.08
Extreme 2.08
13.57
10 years 2.08
Extreme 2.08
23.01
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-03
Director of Finance/CFO 54 2022-08-07
Chief Tech/Sci/R&D Officer - 2024-11-30
Director TitleAgeSince
Director/Board Member 59 2020-05-31
Director/Board Member 66 2021-11-07
Director/Board Member 52 2022-06-03
Date Insider Type Main position Quantity % Market Cap. Importance
9/6/26 Tax

Chairman

-5,116 0.0074%
6/3/26 Free

Director

46,106 0.0670%
6/3/26 Free

Director

46,106 0.0670%
Change 5-day change 1-year change 3-year change Capi.($)
+2.01%+9.54%+7.88%-36.77% 246M
+0.37%+0.65%-23.75%+1.59% 178B
-0.69%+1.29%-3.62%+11.27% 118B
-0.20%-3.98%+6.17%+72.47% 58.92B
-0.24%+1.74%-3.94%-31.61% 49.29B
-0.22%-0.37%+7.26%+35.20% 48.17B
+1.61%+7.61%+17.91%-6.24% 33.72B
-1.49%-2.74% - - 27.76B
-1.17%+4.64%+42.09%-8.18% 25.5B
+1.02%+5.99%+7.20%-19.54% 22.1B
Average +0.10%+2.62%+6.35%+2.02% 56.11B
Weighted average by Cap. -0.08%+1.04%-4.29%+9.67%

Financials

2026 *2027 *
Net sales 122M 106M 101M 91.3M 171M 11.72B 172M 1.2B 465M 5.96B 459M 449M 19.17B 133M 116M 110M 99.59M 187M 12.78B 187M 1.31B 507M 6.5B 500M 489M 20.91B
Net income -46.2M -40.28M -38.04M -34.54M -64.72M -4.43B -64.99M -456M -176M -2.25B -174M -170M -7.25B -57.65M -50.27M -47.47M -43.11M -80.76M -5.53B -81.1M -569M -219M -2.81B -217M -212M -9.05B
Net Debt - -
Logo OraSure Technologies, Inc.
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.
Employees
500
Date Price Change Volume
26-09-18 $3.560 +2.01% 1,339,686
26-09-17 $3.490 +0.29% 355,531
26-09-16 $3.480 +0.58% 415,208
26-09-15 $3.460 +2.67% 1,478,007
26-09-14 $3.370 +3.69% 765,965
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.560USD
Average target price
4.000USD
Spread / Average Target
+12.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OSUR Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!